The UK has approved Australia’s medicinal cannabis company Bod Australia’s clinical trial into the efficacy of its products to treat the effects of long-COVID-19.
It is to note that long-COVID-19 is a condition without a leading treatment where symptoms of initial infection of Coronavirus continues for more than eight weeks.
As per the report, the participants in the trial will be administered daily doses of Bod’s medicinal cannabis product called MediCabilis 5% over a six month period.
The researchers discovered that cannabigerolic acid, or CBGA, and cannabidiolic acid, or CBDA, two cannabinoid acids often present in hemp varietals of cannabis, can bind to the spike protein of SARS-CoV-2, the virus that causes COVID-19.